Market Cap 169.39M
Revenue (ttm) 35.58M
Net Income (ttm) -105.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -296.01%
Debt to Equity Ratio 0.00
Volume 1,814,400
Avg Vol 2,086,538
Day's Range N/A - N/A
Shares Out 71.17M
Stochastic %K 55%
Beta 2.94
Analysts Strong Sell
Price Target $11.50

Company Profile

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 clinical trials targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting BR...

Industry: Biotechnology
Sector: Healthcare
Phone: 617 231 0700
Address:
490 Arsenal Way, Suite120, Watertown, United States
josegodoy
josegodoy Oct. 25 at 10:20 AM
$CCCC I can comfortably argue for a $6-$7 price target (PT). After the aforementioned PT is (/if) achieved and (bullishly) digested properly, we can talk about double digits. An opinion
0 · Reply
lelongduzboob
lelongduzboob Oct. 24 at 9:34 PM
$CCCC Bain Capital Life Sciences Fund II, L.P. (991,188 shares), BCIP Life Sciences Associates, LP (120,722 shares), and BCLS II Equity Opportunities, LP (2,020,000 shares plus warrants for 4,040,000 shares).
0 · Reply
zawojak
zawojak Oct. 23 at 9:53 PM
$CCCC just checked small investors on fintel, many are selling recently or reducing positions. I suppose ot is due to waiting time for the next meaningful milestone 2years +. Oh well I will keep holding and adding on dips close to $2. Still very bullish long term
1 · Reply
Andysss
Andysss Oct. 23 at 7:03 PM
$CCCC One really big bite from the tutes
0 · Reply
zawojak
zawojak Oct. 23 at 1:33 PM
0 · Reply
hk042
hk042 Oct. 23 at 11:59 AM
$CCCC Nice dip. Glad i could add at these levels! Very bullish soon!
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 23 at 12:24 AM
$TNXP $IMRX $NUVB $CCCC $ALT five cheap biotechs worth holding long 💪
0 · Reply
ckeiger
ckeiger Oct. 22 at 2:54 PM
$CCCC Does anyone know why this is down so much?
2 · Reply
zawojak
zawojak Oct. 22 at 2:53 PM
$CCCC share count increased by couple M.
0 · Reply
zawojak
zawojak Oct. 22 at 9:46 AM
$CCCC Just added 100
1 · Reply
Latest News on CCCC
C4 Therapeutics, Inc. - Special Call

Sep 22, 2025, 5:23 AM EDT - 4 weeks ago

C4 Therapeutics, Inc. - Special Call


C4 Therapeutics: An Entry Point If There's Ever Going To Be One

Jun 16, 2025, 1:50 PM EDT - 4 months ago

C4 Therapeutics: An Entry Point If There's Ever Going To Be One


C4 Therapeutics Announces Chief Financial Officer Succession

Sep 5, 2023, 4:01 PM EDT - 2 years ago

C4 Therapeutics Announces Chief Financial Officer Succession


josegodoy
josegodoy Oct. 25 at 10:20 AM
$CCCC I can comfortably argue for a $6-$7 price target (PT). After the aforementioned PT is (/if) achieved and (bullishly) digested properly, we can talk about double digits. An opinion
0 · Reply
lelongduzboob
lelongduzboob Oct. 24 at 9:34 PM
$CCCC Bain Capital Life Sciences Fund II, L.P. (991,188 shares), BCIP Life Sciences Associates, LP (120,722 shares), and BCLS II Equity Opportunities, LP (2,020,000 shares plus warrants for 4,040,000 shares).
0 · Reply
zawojak
zawojak Oct. 23 at 9:53 PM
$CCCC just checked small investors on fintel, many are selling recently or reducing positions. I suppose ot is due to waiting time for the next meaningful milestone 2years +. Oh well I will keep holding and adding on dips close to $2. Still very bullish long term
1 · Reply
Andysss
Andysss Oct. 23 at 7:03 PM
$CCCC One really big bite from the tutes
0 · Reply
zawojak
zawojak Oct. 23 at 1:33 PM
0 · Reply
hk042
hk042 Oct. 23 at 11:59 AM
$CCCC Nice dip. Glad i could add at these levels! Very bullish soon!
0 · Reply
BiotechBonesaw
BiotechBonesaw Oct. 23 at 12:24 AM
$TNXP $IMRX $NUVB $CCCC $ALT five cheap biotechs worth holding long 💪
0 · Reply
ckeiger
ckeiger Oct. 22 at 2:54 PM
$CCCC Does anyone know why this is down so much?
2 · Reply
zawojak
zawojak Oct. 22 at 2:53 PM
$CCCC share count increased by couple M.
0 · Reply
zawojak
zawojak Oct. 22 at 9:46 AM
$CCCC Just added 100
1 · Reply
Andysss
Andysss Oct. 22 at 4:49 AM
$CCCC Some corrections. Schedule 13G filed by Point72 on Oct 21 discloses potential ownership of ~22million shares (9.99 % cap). The position includes ≈14.2 M shares underlying warrants — actual exercisable ownership is limited to 9.99 % due to a blocker provision. Worth noting: about 14.2M of those shares are underlying warrants, with a 9.99% blocker. I see this as major bullish signal
2 · Reply
Letsinvest2024
Letsinvest2024 Oct. 21 at 5:08 PM
$RANI I was mad but look at it now Next $CCCC
0 · Reply
LabPsycho
LabPsycho Oct. 21 at 4:34 PM
$PRLD @pchr 1. Several potential upcoming milestones 2. Molecular glues / degraders seem to be regaining traction (i.e. $CCCC decent results and several big pharma collaborations and $GLUE recent huge partnership with Novartis with tons of $$$ (120M $ UPFRONT) 3. $PRLD fusing PROTAC / molecular degraders with antibodies (great idea IMO with some likely specialized applications) 4. CEO purchased shares about a year ago 5. Generally drifting up with many other beat down biotechs. 6. Recent phantom spike up to $1.91 (then full retrace) suggests wind of a (positive?) development a few weeks ago 7. My molecular dynamic simulation posted here a couple weeks ago (strong bias! LoL)
0 · Reply
4Reel
4Reel Oct. 21 at 3:09 PM
$CCCC broke out of the trading range, above all moving averages 3 dollars by end of month imo
0 · Reply
zawojak
zawojak Oct. 21 at 8:57 AM
0 · Reply
Andysss
Andysss Oct. 21 at 6:17 AM
$CCCC huge news.
1 · Reply
Bruce_Cullen
Bruce_Cullen Oct. 21 at 3:30 AM
$CCCC I'm in... position trader, what should I know about this besides what ive read?
1 · Reply
datapoint1728
datapoint1728 Oct. 21 at 3:11 AM
$CCCC Schedule 13G filed by Steven A. Cohen of Point72 Capital Advisors, Inc. on October 21, 2025 to disclose the ownership of 9.99% of CCCC with 22,647,647 shares. Steven A. Cohen (born June 11, 1956) is an American hedge-fund manager and owner of the New York Mets of Major League Baseball (MLB) since September 14, 2020, owning just over 97% of the team.[3] He is the founder of hedge fund Point72 Asset Management and S.A.C. Capital Advisors.[4]
1 · Reply
vu_jade
vu_jade Oct. 21 at 1:08 AM
$CCCC told you this was a buy months ago
0 · Reply
4Reel
4Reel Oct. 20 at 12:49 PM
$CCCC looks like all the shares was added. Should close the offering. 21.9m shares was the offering at 2.47. I expect them to use the warrants on news related items when volume is present. They have over 300m cash right now including thr costs of this quarter, as last quarter they stated $223M ending june 30.
1 · Reply
Anonymous10000
Anonymous10000 Oct. 19 at 8:44 PM
$CCCC look at $SLS tomorrow. Large gain after hours Friday, but we are just getting started. News Oct. 29.
0 · Reply
zawojak
zawojak Oct. 18 at 9:39 AM
$CCCC Price target decreased by 20% to US$12.00Down from US$15.00, the current price target is an average from 7 analysts. Ref: Simply wall street. I don’t know how hammered a one stock can be. I guess since majority of catalysts news have been shifted to 2028 shorts will have 3 years of scalping here. I have already stopped averaging down my bags inless its below $1.95. I have heavy bags tho.
1 · Reply